Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

To be considered for this study, you must have been recently diagnosed with a specific type of brain tumour called anaplastic oligodendroglioma, anaplastic oligoastrocytoma, or anaplastic astrocytoma. It's important that your tumour has certain genetic features, which doctors will check from a tissue sample.

You should be at least 18 years old. Your general health should be good enough to take part in the study treatments, which doctors will check using various tests. This includes making sure your blood counts and organ functions (like your liver and kidneys) are within a healthy range. You shouldn't be pregnant or breastfeeding, and if you can get pregnant or get someone pregnant, you must use effective contraception during the study.

There are also some things that might mean you can't join. For example, if you have certain other serious medical conditions, or if you've had other cancers recently (with some exceptions like certain skin cancers), you might not be eligible. Also, conditions that might make it hard to take oral medication or attend follow-up appointments could prevent participation.

If you join this study, your treatment will be decided by chance, like flipping a coin. You'll be put into one of four groups: * **Group 1:** You'll receive radiation therapy 5 days a week for about 6 and a half weeks. * **Group 2:** You'll receive radiation therapy 5 days a week for about 6 and a half weeks, and you'll also take oral temozolomide every day during this period. * **Group 3:** You'll receive radiation therapy 5 days a week for about 6 and a half weeks. Then, about a month after radiation finishes, you'll start taking oral temozolomide for 5 days every 28 days. This might continue for up to 12 cycles. * **Group 4:** You'll receive radiation therapy and oral temozolomide every day for about 6 and a half weeks, and then after a break, you'll also receive up to 12 cycles of temozolomide (5 days every 28 days), similar to Group 3.

Throughout the study, you'll have regular hospital visits for assessments such as blood tests, scans, and discussions about your health and any side effects. You'll also be asked to complete questionnaires about your quality of life. These visits will continue for a period after your main treatment ends to monitor your progress. The total duration of your active treatment will depend on which group you are in, but follow-up will last significantly longer.